| Autor: |
Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1984 Nov; Vol. 2 (11), pp. 1255-9. |
| DOI: |
10.1200/JCO.1984.2.11.1255 |
| Abstrakt: |
EST 5275 is a phase II and III study of fluorouracil plus streptozocin (5-FU plus STZ) or doxorubicin in patients with measurable progressive carcinoid tumor. Among one hundred seventy-two cases with no prior chemotherapy and no heart disease, the response rate was 22% for 5-FU plus STZ and 21% for doxorubicin, while the median response duration and median survival were 31 weeks and 64 weeks for the combination and 26 weeks and 48 weeks for doxorubicin. Thirty-three patients who failed 5-FU plus STZ crossed over to doxorubicin and achieved an 18% response. Of the thirty-five patients who failed on doxorubicin, 29% responded to 5-FU plus STZ. Hematologic toxicity was similar for both treatments; however, the 5-FU plus STZ patients experienced more vomiting but acceptable renal toxicity. Both chemotherapy regimens have antitumor activity in carcinoid tumors. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
